Tevogen Bio Holdings (NASDAQ: TVGN) announced the execution of a non-binding Letter of Intent to evaluate the acquisition of Sciometrix Inc., a healthcare technology company known for developing Clinicus, a digital care management platform. The proposed transaction would position Tevogen to acquire a majority voting interest in Sciometrix, marking a potential expansion into healthcare services delivery alongside its existing biotech operations.
Under the terms of the agreement, Tevogen intends to integrate Sciometrix's Clinicus platform with its Tevogen.AI division, combining digital care management capabilities with artificial intelligence functionality. The strategic combination would position the combined entity to generate revenue through healthcare services while maintaining its biotechnology operations, creating a hybrid business model bridging pharmaceutical development and digital health management.
The Letter of Intent remains non-binding, and the transaction is subject to further due diligence and negotiation of definitive agreements. No timeline for completion of the proposed acquisition was disclosed in the announcement.